A Double Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs NIC 002 (Primary)
- Indications Smoking withdrawal; Substance-related disorders
- Focus Therapeutic Use
- 04 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2009 Primary endpoint 'Clinical response' has not been met.